Pelthos Therapeutics Inc. Increase (Decrease) in Prepaid Expense
Pelthos Therapeutics Inc. (PTHS) reported Increase (Decrease) in Prepaid Expense of -$113.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInPrepaidExpense · last filed 2026-08-13
- Pelthos Therapeutics Inc. increase (decrease) in prepaid expense for the quarter ending 2026-06-30 was $385.00K.
- Pelthos Therapeutics Inc. increase (decrease) in prepaid expense for the quarter ending 2026-03-31 was -$498.00K.
- Pelthos Therapeutics Inc. increase (decrease) in prepaid expense for the quarter ending 2025-12-31 was -$531.00K.
- Pelthos Therapeutics Inc. increase (decrease) in prepaid expense for the quarter ending 2025-09-30 was $1.46M, a 100.03% increase year-over-year.
- Pelthos Therapeutics Inc. increase (decrease) in prepaid expense for fiscal 2025 was $880.00K, a 2.21% increase from fiscal 2024.
- Pelthos Therapeutics Inc. increase (decrease) in prepaid expense for fiscal 2024 was $861.00K.
| Period end | Increase (Decrease) in Prepaid Expense 3 month | Increase (Decrease) in Prepaid Expense 3 month as first filed | Increase (Decrease) in Prepaid Expense 6 month | Increase (Decrease) in Prepaid Expense 6 month as first filed | Increase (Decrease) in Prepaid Expense 9 month | Increase (Decrease) in Prepaid Expense 9 month as first filed | Increase (Decrease) in Prepaid Expense 12 month | Increase (Decrease) in Prepaid Expense 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $385.00K derived: 10-Q 6 month − 10-Q/A 3 month · filed 2026-08-13 | -$113.00K 10-Q · filed 2026-08-13 | -$644.00K derived: sum of 3 quarters · filed 2026-08-13 | $820.00K derived: sum of 4 quarters · filed 2026-08-13 | ||||
| 2026-03-31 | -$498.00K 10-Q/A · filed 2026-08-13 | -$1.03M derived: sum of 2 quarters · filed 2026-08-13 | $435.00K derived: sum of 3 quarters · filed 2026-08-13 | $431.00K derived: sum of 4 quarters · filed 2026-08-13 | ||||
| 2025-12-31 | -$531.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-19 | $933.00K derived: sum of 2 quarters · filed 2026-03-19 | $929.00K derived: sum of 3 quarters · filed 2026-08-13 | $880.00K 10-K · filed 2026-03-19 | ||||
| 2025-09-30 | $1.46M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | $1.46M derived: sum of 2 quarters · filed 2026-08-13 | $1.41M 10-Q · filed 2025-11-13 | $1.38M derived: sum of 4 quarters · filed 2026-08-13 | ||||
| 2025-06-30 | -$4.00K derived: 10-Q 6 month − 10-Q/A 3 month · filed 2026-08-13 | -$53.00K 10-Q · filed 2026-08-13 | -$52.96K 10-Q · filed 2025-08-13 | -$82.00K derived: sum of 3 quarters · filed 2026-08-13 | $649.90K derived: sum of 4 quarters · filed 2026-08-13 | |||
| 2025-03-31 | -$49.00K 10-Q/A · filed 2026-08-13 | -$48.96K 10-Q · filed 2025-05-13 | -$78.00K derived: sum of 2 quarters · filed 2026-08-13 | $653.90K derived: sum of 3 quarters · filed 2026-08-13 | $591.07K derived: sum of 4 quarters · filed 2026-08-13 | |||
| 2024-12-31 | -$29.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-19 | $702.90K derived: sum of 2 quarters · filed 2026-03-19 | $640.07K derived: sum of 3 quarters · filed 2026-03-19 | $861.00K 10-K · filed 2026-03-19 | $65.30K 10-K · filed 2025-03-27 | |||
| 2024-09-30 | $731.90K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | $669.07K derived: sum of 2 quarters · filed 2025-11-13 | $890.00K 10-Q · filed 2025-11-13 | $94.58K 10-Q · filed 2024-11-13 | ||||
| 2024-06-30 | -$62.83K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-13 | $158.10K 10-Q · filed 2025-08-13 | ||||||
| 2024-03-31 | $220.93K 10-Q · filed 2025-05-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Atara Biotherapeutics, Inc. (ATRA) | United States | $0.086B | -6.48 |
| COGNITION THERAPEUTICS INC (CGTX) | United States | $0.090B | -6.52 |
| Vaxart, Inc. (VXRT) | United States | $0.080B | 3.84 |
| Kalaris Therapeutics, Inc. (KLRS) | United States | $0.073B | -2.19 |
| Cardiff Oncology, Inc. (CRDF) | United States | $0.101B | -2.22 |
| CHAMPIONS ONCOLOGY, INC. (CSBR) | United States | $0.070B | -68.02 |
| BioStem Technologies, Inc. (BSEM) | United States | $0.069B | |
| Eloxx Pharmaceuticals, Inc. (ELOX) | United States | $0.065B | |
| Black Diamond Therapeutics, Inc. (BDTX) | United States | $0.109B | -2.48 |
| MiNK Therapeutics, Inc. (INKT) | United States | $0.063B | -5.37 |